InMed Pharmaceuticals (INM) Stock Statistics & Valuation Metrics

InMed Pharmaceuticals has a market cap or net worth of $3.51M. The enterprise value is $1.14B.

InMed Pharmaceuticals has 1,207,186 shares outstanding. The number of shares has decreased by -2.65% in one year.

InMed Pharmaceuticals’s return on equity (ROE) is -0.83 and return on invested capital (ROIC) is 0.00%.

The current PE Ratio of InMed Pharmaceuticals is -4.99. InMed Pharmaceuticals’s PEG ratio is 0.06.

In the last 12 months, InMed Pharmaceuticals had revenue of 4.60M and earned -7.68M in profits. Earnings per share was -1.01.

In the last 12 months, operating cash flow was -7.81B and capital expenditures 0.00, giving a free cash flow of -7.81B billion.

InMed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

InMed Pharmaceuticals upcoming earnings date is Sep 19, 2025, Before Open (Confirmed).

InMed Pharmaceuticals as a current ratio of 4.41, with Debt / Equity ratio of 3.24%

In the past 12 months, InMed Pharmaceuticals has paid 7.10K in taxes.

InMed Pharmaceuticals EV to EBITDA ratio is -4.63, with an EV/FCF ratio of -4.68.

InMed Pharmaceuticals has $4.72B in cash and marketable securities with $419.35M in debt, giving a net cash position of -$4.30B billion.

Gross margin is 33.93%, with operating margin of 0.00%, and net profit margin of -166.94%.

The average price target for InMed Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―